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oOne of the great public health achievements of the
past century was the control of many infectious diseases
by vaccination. Especially impressive were the global
eradication of smallpox, the “most terrible of the minis-
ters of death” (declared in 1980), and elimination of in-
digenous poliomyelitis from the whole of the Americas by
1991 and of indigenous measles from several countries
during the 1990s.
Many infectious diseases are still very common in the
world today despite improvements in living conditions in
developed countries. Although it is 10th on the 1998
World Health Report’s (WHO, Geneva) list of infectious
diseases causing high global mortality and morbidity,
HIV/AIDS must now be recognized as posing the great-
est infectious disease threat to mankind since the 1918–
1919 influenza pandemic which killed more than 20 mil-
lion people. As we enter the next millennium, the picture
is grim, especially for some developing countries—
about 50 million infected people, staggering economic
costs, serious depletion of those in the most productive
age group, all of which threaten political and social
stability. Countries in sub-Saharan Africa and the Indian
subcontinent and neighboring countries are particularly
at risk.
PROSPECTS FOR THE PREVENTION/CONTROL OF
HIV INFECTION BY VACCINATION
Though there are several behavioral approaches to
inimize the risk of infection, there is general agreement
hat development of a vaccine offers the best hope for an
ffective way of controlling and lessening the impact of
he pandemic.
PRODUCTION OF ANTIBODY RESPONSES
WHICH BLOCK HIV INFECTION
Until recently, vaccine developers have understand-
bly placed most emphasis on the induction of an anti-f1 Address correspondence to author. Fax: 61-2-6249-2595.
227ody response which neutralizes the infectivity of the
irus, thus preventing infection or greatly minimizing the
nfectious dose. Most current vaccines are against
gents which are antigenically stable, the major excep-
ion being the influenza virus where, because of anti-
enic drift (frequent mutations), a new vaccine matching
he antigenic specificity of circulating strains is made
ach year. The very high level of mutations in the HIV
ntigens, particularly the env surface antigen, and the
nstability and low immunogenicity of the trimeric env
ligomer (Table 1) have contributed to the difficulty of
nducting a strong antibody response which effectively
eutralizes a range of new viral isolates. There are two
eceptors for the virus on susceptible cells: the CD4
olecule and a chemokine receptor molecule. Immuniz-
ng mice with a chemically fixed complex between the
nv protein and a cell expressing both receptors induces
he formation of antibodies which neutralize a wide
ange of HIV field isolates. It is believed that the distor-
ion caused by the env-binding process results in the
normally) temporary exposure of a conserved region. It
s a challenge to convert this result to a practical method
f developing an effective prophylactive vaccine.
PRODUCTION OF EFFECTOR CELL-MEDIATED
IMMUNE RESPONSES WHICH CLEAR/LIMIT
VIRAL INFECTIONS
Though many vaccines/vaccine candidates induce pri-
marily a humoral response, and some induce both an
antibody and effector CMI response (e.g., a live chimeric
vector or a DNA plasmid preparation), another approach
is to develop a vaccine which primarily and maximally
induces mainly a very strong memory CD41 TH1 lym-
phocyte and especially CD81 CTL responses.
There is compelling evidence for the importance of
CD81 CTLs in controlling/clearing many viral infections:
11. Transfer of CD8 CTL preparations can clear virus
rom murine infected organs or protect from death fol-
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228 MINIREVIEWlowing infection with a lethal dose of virus (Ada and
Ramsay, 1997);
2. In at least three cases of murine infection with a
natural pathogen [lymphocytic choriomeningitis (LCM)
virus, ectromelia, and Theiler’s virus], CTLs are essential
for controlling/clearing the infection.
Protocols are now available which induce primarily an
effector CMI response, and although some antibody may
also be produced, this can be shown to be irrelevant.
This has allowed the following question to be answered:
Can preimmunization of mice to induce a virus-specific
CTL response result in clearance of a later infection by
that virus which otherwise would persist? The answer is
yes! Mice of particular MHC haplotypes immunized with
a recombinant vaccinia expressing certain LCMV-spe-
cific CTL epitopes were later protected against the es-
tablishment of a persistent LCMV infection (Oldstone et
al., 1993).
REASONS FOR CONSIDERING THIS APPROACH IN
THE CASE OF HIV INFECTIONS
There are three categories of reasons for implement-
ng this approach in the case of HIV:
1. The present difficulties of inducing a broadly pro-
ective humoral response, as indicated above, although
opefully these may be overcome in time;
2. Experiments of nature, i.e., the presence of CTL
ctivity in HIV-negative and seronegative individuals ex-
osed to HIV, namely infants born to infected mothers,
ong-term sexual partners of infected adults, some Afri-
an prostitutes, and health-care workers. In a few cases,
race amounts of virus-specific IgA/sIgA have also been
etected.
TABLE 1
Major Difficulties Associated with HIV Vaccine Development
The agent
1. High mutation rate, resulting in great antigenic variation
2. Surface antigen (env) is highly glycosylated and poorly
immunogenic; it exists as a labile trimer
The infection and disease
1. Infection can be transmitted by productively or latently infected
cells
2. Viral cDNA integrates into the host cell genome
3. Protective immunity rarely occurs after natural infection
4. Mutations in epitopes (T and B cells) occur during infection
5. Suppression of effector T cells occurs
6. Downregulation of expression of class I MHC antigens on
infected cells
7. Crucial cells of the immune system become infected
8. Apoptosis of infected cells can be delayed
9. A readily available, affordable, and susceptible animal model
which mimics the human disease is not available3. There is increasingly more direct evidence of the
mportance of CTLs in the control of HIV/SIV/SHIV inhumans/monkeys (Table 2).
The initial emphasis on developing an HIV vaccine
based entirely on inducing a humoral response was
overtaken in the mid-1990s by approaches in which the
initial immunization primed for both a humoral and CD81
CTL response (chimeric live vector) and the booster
immunization (env antigen) should mainly enhance the
humoral response. The present aim is to prime and
boost immunizations to induce a very great memory CTL
response in most recipients. Though there may be sev-
eral ways of achieving this, priming with a DNA prepa-
ration followed by a chimeric live poxvirus vector is
effective in mice and monkeys (in mice, reversing this
sequence is less effective). This approach has resulted
in the control of an HIV infection in Macaca nemestrina
monkeys (Kent et al., 1998), and monkeys immunized in
his way survived a challenge with a pathogenic SHIV
reparation (Robinson et al., 1999). It is possible that
nclusion of DNA coding for selected cytokines such as
FN-g or IL-12 into either of the preparations could en-
ance this response still further.
THE TASK AHEAD
Trialing the above approach with HIV is a severe test
ut is warranted in view of the rapidly expanding global
hreat of this infection. The primary aim is to convert what
s in most cases a chronic persisting and fatal infection
nto an acute (i.e., nonpersisting) infection. Following a
ucosal exposure to the virus (e.g., a vaginal infection),
nfected dendritic cells carry the virus to draining lymph
odes where naive CD81 T lymphocytes are activated.
The build up to a high level of CTL activity is generally
too slow to prevent a strong viremia from occurring, even
though in time CTLs greatly reduce this large viral load.
TABLE 2
Evidence for the Importance of CTLs in the Control
of HIV/SIV/SHIV in Humans/Monkeys
(i) Long-term nonprogressors to AIDS have persisting strong CTL
responses, mainly to conserved epitopes
(ii) Antiviral CD81 CTLs have regularly been found in cytobrush
specimens from the cervix of HIV-infected women with high
CD41 T cell counts
(iii) Certain class I HLA specificities (B27, A32, B18, A6802) are
associated with protective effects, whereas others (B35, B39) are
associated with rapid progression to AIDS (In time and in the
absence of intervention, these associations might strengthen.
For example, HLA Bw53 is associated with resistance to severe
malaria in the Gambia. In sub-Saharan Africa, this allele occurs
in 15–40% of the population, compared to ,1% in Caucasians
and Asians, suggesting strong selection over time)
(iv) Transfer of anti-CD8 sera causes a surge of growth in SIV, SHIV-
infected monkeys (two reports)
(v) CD81 T cells are strong producers of HIV-suppressor factors,
including chemokines, which can restrict infection of susceptible
cells
ction is
viremia
229MINIREVIEWFigure 1, curve A, illustrates this usual pattern of viral
titers following infection. In contrast, after immunization,
the much greater ease of activation of memory CTLs,
together with their greater frequency compared to nor-
mal levels of CTL precursors (a pattern generally seen in
in vitro limit dilution analyses after a viral infection), will
result in the more rapid appearance and higher level of
effector CTLs. Their secretion of HIV-suppressor sub-
stances and ability to lyse cells 1–2 h after infection (a
pattern seen with other viral infections) should greatly
reduce the continuing cycles of infection of susceptible
cells. Optimally, the infection could be controlled to such
an extent that any viremia is too low to be detected (Fig.
1, curve B). Activated CTLs should rapidly disperse
around the body, including to the site of the original
infection, and these individuals may become nonpro-
gressors. Figure 1, curve C, illustrates that in some cases
viremia is still detectable but at a greatly reduced level,
so that these individuals become very slow progressors
and should be less infectious for others.
CONTROLLING FUTURE INFLUENZA PANDEMICS
If a high proportion of volunteers vaccinated according
to this schedule develop a strong HIV-specific CTL re-
sponse, applying this approach to controlling other in-
FIG. 1. HIV levels, initially in draining lymph nodes (A) and then in b
postulated to occur in individuals preimmunized with a vaccine genera
titer; abscissa, time (weeks, months, years) after infection. (Curve A)
quantities of virus are exported from the draining lymphoid tissue, result
B) Optimal effect pattern in immunized individuals. Viral progeny produ
C) Minimal effect pattern in immunized individuals. A greatly reducedfections of especially RNA viruses which display great
antigenic variation and can result in chronic infectionsshould be considered. Influenza A virus is a prime ex-
ample, as many virologists consider that it is only a
question of time before a new pandemic occurs, due to
the emergence of an animal or bird/human reassortant
(antigenic shift) which could spread around the world
very rapidly. Estimates of the economic impact of such a
pandemic in the United States range from U.S. $71 to
$166 billion, excluding disruptions to commerce and so-
ciety (Meltzer et al., 1999). In 1997, an H5N1 influenza
strain from chickens fortunately infected few people in
Hong Kong and there was no human to human transmis-
sion.
The epitopes of the trimeric oligomers of hemaggluti-
nin molecules of the H1, H2, or H3 strains infecting
humans recognized by infectivity-neutralizing antibody
are very variable. Preassessment of the required anti-
hemagglutinin antibody specificity to prevent infection by
a novel reassortant is not feasible. In contrast, a vacci-
nation approach based on CTL generation makes sense
because the sequences of the influenza virus internal
antigens, which are the main sources of CTL epitopes,
are highly conserved.
However, an immunization protocol based on a hu-
moral response which provides cross-protection against
different A strain viruses may still be possible. Mice
), following a mucosal HIV infection in normal individuals (known) or
trong cell-mediated (cytotoxic T lymphocytes) response. Ordinate, HIV
usually observed in unimmunized individuals. After infection, large
marked viremia, which is reduced by the normal CTL response. (Curve
largely limited to lymphoid tissue, with no detection of viremia. (Curve
occurs.lood (B
ting a s
Pattern
ing in arepeatedly immunized with protein conjugates, each
containing many copies of the external domain of the
230 MINIREVIEWlargely conserved M2 surface protein of the influenza
virus, have now been shown to survive a lethal dose of a
heterologous influenza virus challenge, an antibody-me-
diated effect (Neirynek et al., 1999). Compared to the
hemagglutinin, there are relatively few copies of the M2
protein per virus particle. This is an encouraging finding,
and though the influenza virus is not a natural pathogen
of mice, the results of clinical trials are eagerly awaited.
The new antineuraminidase drugs could also help to
contain a major influenza pandemic if and when it oc-
curs.
LEARNING FROM LISTERIA
A CTL response specific for listeriolysin O (LLO), a
secreted pore-forming toxin, can clear a murine Listeria
monocytogenes infection. Though immune serum from a
normal infection is nonprotective (first shown by George
Mackaness), transfer of an anti-LLO monoclonal anti-
body to SCID mice considerably enhanced their survival
rate following an otherwise mainly lethal infection (Edel-
son et al., 1999).
THE FUTURE
These examples illustrate two possible approaches
for future vaccine development against difficult intracel-
lular infectious agents. They are the use of immunization
protocols which result in either:
1. A rapid, greatly enhanced CMI, especially a CTL,
response to conserved peptide sequences following
later exposure to the wild-type agent; or2. A strong antibody response to components ex-
pressing conserved B cell epitopes, which, during a
normal infection, may be exposed only momentarily, are
poorly immunogenic, or are expressed at too low a level
to induce a significant antibody response.
Both approaches should be tried against other intra-
cellular infectious agents which are globally important
causes of severe morbidity and/or mortality, such as
hepatitis C virus. The increasing availability of genomic
sequences of important intracellular bacteria and para-
sites should facilitate these approaches.
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